129973-02-0

Basic information

• Product Name: Alanine, N-(4-chlorobenzoyl)-2-methyl-
• Synonyms: Alanine, N-(4-chlorobenzoyl)-2-methyl-;2-[(4-Chlorobenzoyl)amino]-2-methylpropanoic acid;2-(4-Chlorobenzamido)-2-methylpropanoic acid
• CAS NO: 129973-02-0
• Molecular Formula: C₁₁H₁₂ClNO₃
• Molecular Weight: 241.68
• Mol File: 129973-02-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Alanine, N-(4-chlorobenzoyl)-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Alanine, N-(4-chlorobenzoyl)-2-methyl-(129973-02-0)
• EPA Substance Registry System: Alanine, N-(4-chlorobenzoyl)-2-methyl-(129973-02-0)

Safety Data

• Hazardous Substances Data: 129973-02-0(Hazardous Substances Data)

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 62-57-7 2-Aminoisobutyric acid 

Downstream Products

• 5106-98-9 4-chlorosalicylic acid 
• 619-56-7 4-chlorobenzamide 

Relevant articles and documents

Cu(II)-promoted oxidative C-N bond cleavage of N-benzoylamino acids to primary aryl amides

A novel protocol for CuCl2-promoted oxidative C-N bond cleavage of N-benzoyl amino acids was developed. It is the first example of using accessible amino acid as an ammonia synthetic equivalent for the synthesis of primary aryl amides via CuCl2-promoted oxidative C-N bond cleavage reaction. The present protocol shows excellent functional group tolerance and provides an alternative method for the synthetic of primary aryl amides in 84-96% yields.

Cu(II)-catalyzed decarboxylation/elimination of N-arylsulfonyl amino acids to primary aryl sulfonamides

A novel protocol for CuO-catalyzed decarboxylation/elimination of N-arylsulfonyl amino acids was developed. It is the first example of using an accessible amino acid as an ammonia synthetic equivalent for the synthesis of primary aryl sulfonamides via oxidative decarboxylation/elimination reactions. The present protocol shows excellent functional group tolerance and provides an efficient method for the synthesis of primary aryl sulfonamides in excellent yields.

Proteasome inhibitors

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.